Introduction of exogenous wild ‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells.

Introduction of exogenous wild‑type p53 mediates the regulation of oncoprotein 18/stathmin signaling via nuclear factor‑κB in non‑small cell lung cancer NCI‑H1299 cells. Oncol Rep. 2019 Jan 10;: Authors: Chen S, Zhao Y, Shen F, Long D, Yu T, Lin X Abstract Our previous studies demonstrated that high expression of oncoprotein 18 (Op18)/stathmin promotes malignant transformation of non‑small cell lung cancer NCI‑H1299 cells. Investigation of the cellular settings determined that NCI‑H1299 cells were genetically p53 deficient. In order to determine whether p53 deficiency is associated with Op18/stathmin‑mediated high levels of malignancy, exogenous wild‑type p53 (p53wt) was introduced into NCI‑H1299 cells in the present study to observe Op18/stathmin signaling changes and malignant behaviors. The results indicated that p53 downregulated Op18/stathmin expression and phosphorylation at the Ser25 and Ser63 sites in NCI‑H1299 cells, and the abilities of proliferation, colony formation and migration in multi‑dimensional spaces were simultaneously reduced. Introduction of p53wt inhibited the expression of the transcription factor nuclear factor‑κB (NF‑κB), and the activities of the Op18/stathmin upstream kinases cyclin‑dependent 2 (CDC2) and extracellular signal‑regulated kinase (ERK). Furthermore, blocking of NF‑κB signaling decreased CDC2 and ERK activation. Additionally, p53 intervention attenuated ...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research

Related Links:

Publication date: Available online 23 March 2019Source: The Annals of Thoracic SurgeryAuthor(s): Donglai Chen, Yiming Mao, Junmiao Wen, Yunlang She, Erjia Zhu, Feng Zhu, Yongsheng Zhang, Min Fan, Chang Chen, Yongbing ChenAbstractBackgroundA series of studies have assessed the clinicopathological features and prognostic impact of STAS in non-small cell lung cancer (NSCLC) bringing conflicting findings so far. We performed a systematic review and meta-analysis to synthesize the available evidence regarding to the prognostic value of STAS in NSCLCs.MethodsStudies were identified by searching databases including PubMed, EMBASE...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Authors: Hu X, Duan L, Liu H, Zhang L Abstract Long noncoding RNAs (lncRNAs) played in authentic biological cell roles such as cell apoptosis, cycle, differentiation, development, migration and invasion. However, the expression pattern and function of a new lncRNA LINC01296 in non-small cell lung cancer (NSCLC) are unknown and need to be studied. In our study, we indicate that the expression of LINC01296 was overexpressed in NSCLC samples compared to adjacent non-tumor tissues. Ectopic expression of LINC01296 promoted NSCLC cell proliferation and migration. Moreover, we demonstrated that LINC01296 has a potential b...
Source: American Journal of Translational Research - Category: Research Tags: Am J Transl Res Source Type: research
Authors: Wierzba W, Śliwczynski A, Karnafel W, Dziemidok P, Pinkas J Abstract Introduction: Many epidemiological studies show a correlation between the risk of cancer and type 2 diabetes mellitus in various populations. Material and methods: The material was obtained from the database of the National Health Fund. This publication presents a comparison of the incidence of new malignancies in rural and urban populations of diabetic patients in Poland based on the database of the National Health Fund for the period between 1.05.2008 and 30.09.2014. Results: Comparison of the mean incidence of selected maligna...
Source: Archives of Medical Science - Category: General Medicine Tags: Arch Med Sci Source Type: research
In this study, we aimed to identify the profiles of PRCC expression in Korean NSCLC patients and to elucidate the role of PRCC overexpression on lung tumorigenesis. MATERIALS AND METHODS: We performed immunohistochemistry analysis with a tissue array containing 161 primary NSCLCs. Small interfering RNA targeting PRCC (siPRCC) was transfected into two lung cancer cell lines (NCI-H358 and A549), after which tumor growth, migration, and invasion were observed. Expressions of cell proliferation-, cell cycle-, and metastasis-related molecules were examined by Western blot analysis. We also explored the in vivo effect of PR...
Source: Yonsei Medical Journal - Category: Universities & Medical Training Authors: Tags: Yonsei Med J Source Type: research
CONCLUSION: In this population of lung cancer patients admitted into ICU, independent predictors of hospital mortality are determined by the physiological perturbations induced by the acute presenting complication. After recovery from this, prognosis is again determined by the characteristics of the underlying cancer. PMID: 30898468 [PubMed - as supplied by publisher]
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Tags: Rev Mal Respir Source Type: research
This study evaluated its diagnostic value for differentiating between NSCLC and high-grade neuroendocrine tumor (HGNET).MethodsStathmin-1 protein expression was assessed by immunohistochemistry (IHC) in surgical specimens of 414 NSCLC (305 adenocarcinoma [AD], 102 squamous cell carcinoma [SCC], 7 large-cell carcinoma [LA]), 5 typical carcinoid (TC; a low-grade neuroendocrine tumor), and 34 HGNET (17 small-cell carcinoma [SCLC] and 17 large-cell neuroendocrine carcinoma [LCNEC]) and biopsy specimens of 57 NSCLCs (29 AD and 28 SCC) and 42 HGNETs (17 LCNEC and 25 SCLC). We also analyzed stathmin-1 mRNA levels in 81 NSCLC and ...
Source: The Annals of Thoracic Surgery - Category: Cardiovascular & Thoracic Surgery Source Type: research
Xalkori (crizotinib) has had great success treating ALK positive lung cancer patients. The next generation of ALK inhibitors are also showing great promise. In this video, Dr. Leena Gandhi of Dana-Far... Author: cancergrace Added: 03/23/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Xalkori (critzotinib) was the first approved treatment for ALK+ and ROS1 lung cancer. Since then, other drugs have been approved or are currently undergoing scientific review. In this video, Dr. Owoni... Author: cancergrace Added: 03/23/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
The brain is a common site of disease in patients with ALK+ lung cancer. In this video, Dr. Horn illustrates the line-up of ALK+ treatments and how they work breaking through the blood/brain barrier. Author: cancergrace Added: 03/23/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
Metabolic dependence of cyclosporine A on cell proliferation of human non‑small cell lung cancer A549 cells and its implication in post‑transplant malignancy. Oncol Rep. 2019 Mar 18;: Authors: Qin X, Chen Z Abstract Cyclosporine A (CsA), a widely used immunosuppressant to prevent organ transplant rejection, is associated with an increased cancer risk following transplantation, particularly in the lung. However, the underlying mechanisms remain unclear. In the present study, using human non‑small cell lung cancer A549 cells, it was determined that CsA (0.1 or 1 µM) promoted ce...
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
More News: Cancer | Cancer & Oncology | Genetics | Lung Cancer | Study